Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats

Sun Shin Yi; Hyun-Jin Kim; Seon-Gil Do; Yoon-Bok Lee; Hee Jin Ahn; In Koo Hwang; Yeo Sung Yoon

doi:10.5115/acb.2012.45.2.114

Journal List > Anat Cell Biol > v.45(2) > 1071676

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yi, Kim, Do, Lee, Ahn, Hwang, and Yoon: Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats

Original Article

Neurobiology

Anatomy & Cell Biology

Anatomy & Cell Biology 2012; 45(2): 114-120.

Published online: 30 June 2012

DOI: https://doi.org/10.5115/acb.2012.45.2.114

Arginine vasopressin (AVP) expressional changes in the hypothalamic paraventricular and supraoptic nuclei of stroke-prone spontaneously hypertensive rats

Sun Shin Yi¹, Hyun-Jin Kim², Seon-Gil Do², Yoon-Bok Lee³, Hee Jin Ahn¹, In Koo Hwang⁴, Yeo Sung Yoon⁴

¹Department of Biomedical Laboratory Science, College of Biomedical Sciences, Soonchunhyang University, Asan, Korea.

²Life Science Research Institute, Unigen Inc., Cheonan, Korea.

³Department of Laboratory Animal Research, Central Research Institute, Dr. Chung's Food Co. Ltd., Cheongju, Korea.

⁴Department of Anatomy and Cell Biology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, Seoul, Korea.

Corresponding author: Yeo Sung Yoon. Department of Anatomy and Cell Biology, College of Veterinary Medicine and Research Institute for Veterinary Science, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 151-742, Korea. Tel: +82-2-880-1264, Fax: +82-2-871-1752, ysyoon@snu.ac.kr

Received 8 May 2012 Revised 29 May 2012 Accepted 30 May 2012

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Arginine vasopressin (AVP) is a neuropeptide with vasoconstrictive, antidiuretic, cardiovascular regulative and hepatic glycogenolysis effects, that also affects other behaviors including modulating learning. A number of studies on AVP regulation have been conducted in various metabolic diseases (disorders). In this study, the immunoreactivities of AVP in the paraventricular nucleus (PVN) and supraoptic nucleus (SON) and mRNA expressions in the hypothalamus were investigated by immunohistochemistry and quantitative real-time PCR (RT-qPCR) in stroke-prone spontaneously hypertensive rats at different ages (i.e., at postnatal months [PM] 1, 8, and 12). Blood glucose levels in the PM 8 group were higher than in the other groups. However, cresyl violet positive neurons were detected in the PVN and SON of all animals, and numbers of cresyl violet positive neurons were similar in all aged groups. In addition, AVP immunoreactivity was detected in the PVN and SON of all age groups, and AVP immunoreactivity and mRNA expression levels were found to be increased in proportion to age by immunohistochemistry and RT-qPCR. These results suggest that the diabetic condition is temporally generated after hypertension has developed. Furthermore, our findings suggest that increased AVP expressions in the hypothalamic PVN and SON are associated with hypertension by age.

Keywords: Arginine vasopressin, Paraventricular hypothalamic nucleus, Supraoptic nucleus, Stroke-prone spontaneously hypertensive rats

Introduction

Arginine vasopressin (AVP) is synthesized in magnocellular neurons of the paraventricular nucleus (PVN), and in the supraoptic nucleus (SON) of the hypothalamus, and is then transported axonally and released into the systemic circulation from nerve terminals in the posterior pituitary. AVP is a neuropeptide that has vasoconstrictive, antidiuretic, cardiovascular regulatory and other behaviors including affecting learning [1-3].

Several studies have investigated hypertension regulation using spontaneously established animal model systems, such as, stroke-prone spontaneously hypertensive rats (SHRSP) or a spontaneously hypertensive rat (SHR) in association with AVP. Moreover, AVP has been found to be strongly related to arterial blood pressure regulation in various experimental settings [4-8]. However, it has not been understood how AVP is regulated in the hypothalamic region in SHRSP rats. These rats characteristically show a continuous increase in aortic blood pressure and usually die before they are 40 weeks old from cerebral hemorrhage or heart failure [9]. In addition, several investigations on AVP regulation have associated metabolic diseases like diabetes mellitus, and age related changes in AVP have been well demonstrated in other animal models [10-14]. However, little is known about the relationship between AVP and hypertension in brain with respect to age. In order to determine the nature of the relationship between AVP and hypertension, we examined pre-hypertensive rats, i.e., at postnatal month (PM) 1, and post-hypertensive rats at PM 8 and 12.

In this study, we investigated age-related morphology, AVP immunoreactivity and its mRNA expressional changes in the hypothalamic PVN and SON.

Materials and Methods

Experimental animals and check of blood glucose level

Male SHRSPs were obtained from the Experimental Animal Center, Hallym University, Chuncheon, Korea. PM 1 (n=10), PM 8 (n=10), and PM 12 (n=10) rats in each strain were housed in a conventional state under adequate temperature (23℃) and humidity (60%) control with a 12-hour light/12-hour dark cycle, with free access to food and water. We adhered to the procedures for handling and caring for the animals as per the NIH Guide for the Care and Use of Laboratory Animals (NIH publication No. 85-23, 1985, revised 1996).

All the experiments were conducted to minimize the number of animals used and the suffering caused by the procedures. The blood glucose levels of animals were checked with a validated one touch basic glucose measurement system.

Cresyl violet (CV) staining

To observe the overall morphology of PVN and SON, SHRSP rats in PM 1, PM 8, and PM 12 group (n=5 at each time point) were used for CV staining. In brief, the sections were mounted on gelatin-coated microscopy slides. CV acetate (Sigma, St. Louis, MO, USA) was dissolved at 1.0% (w/v) in distilled water, and glacial acetic acid was added to this solution. Before and after staining for 2 minutes at room temperature, the sections were washed twice in distilled water. The fixed brain tissues were dehydrated by immersion for 2 hours in 50%, 70%, 80%, 90%, 95%, and 100% ethanol baths in succession at room temperature. After dehydration, the sections were mounted with Canada balsam (Kanto Chemical, Tokyo, Japan).

Immunohistochemistry

An immunohistochemistry was performed under the same conditions for each group. Sections were treated with 0.3% hydrogen peroxide (H₂O₂) in phosphate buffered saline (PBS) for 30 minutes and then 10% normal goat serum in 0.05 M PBS for 30 minutes. They were then incubated with diluted rabbit anti-AVP antibody (1 : 2,000, Phoenix Pharmaceuticals, Belmont, CA, USA) overnight at room temperature and then exposed to biotinylated goat anti-rabbit IgG and streptavidin peroxidase complex (1 : 200, Vector, Burlingame, CA, USA). Sections were then visualized by staining with 3,3'-diaminobenzidine in 0.1 M Tris-HCl buffer (pH 7.2), and then mounted on gelatin-coated slides then dehydrated. A negative control test was carried out using pre-immune serum instead of the primary antibody in order to establish the specificity of immunostaining. The tissue in negative control contained no AVP immunoreactivity in any structure.

RNA isolation and quantitative real-time PCR (RT-qPCR) for AVP

The instruments used were treated with anti-RNase free solution. The skull was accessed aseptically and brains removed. A brain matrix was used to isolate the hypothalamic section which was dissected out using anatomical landmarks (medial to optic tract, and ventral to the mammillothalamic tract). Frozen hypothalami were homogenized and total RNA was isolated using a PureLink Micro-to-Midi total purification system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions.

Reverse transcriptase and PCR procedures were carried out separately. A qPCR was performed using SYBR Green kit (Applied Biosystems, Warrington, UK) for AVP. RT-qPCR analysis of the mRNA expressions was carried out in a Stepone (Applied Biosystems, Foster City, CA, USA) sequence detector system 40 times with a 94℃ denaturation of 15 seconds, and annealing at 60℃ for 1 minute, The used primers for AVP and β-actin are F: 5'-CAG ATG CTC GGC CCG AAC-3'/R: 5'-TTC CAG AAC TGC CCA AGA-3' and F: 5'-TTG CTG ACA GGA TGC AGA A-3'/R: 5'-ACC AAT CCA CAC AGA GTA CTT-3' [15], respectively. The data were collected and analyzed using OneStep soft ware (Applied Biosystems). Relative determination of the CT values for references and target genes in each was set according to the 2^-ΔΔCT method described by the manufacturer.

Quantification of data and statistical analysis

All measurements were performed to ensure objectivity under blind conditions, by two observers per experiment, who performed analyses using identical conditions.

In order to quantitatively analyze AVP immunoreactivity, the corresponding PVN and SON areas were measured using in total 10 sections per animal. Images of all AVP immunoreactive structures were taken using a BX51 light microscope (Olympus, Tokyo, Japan) equipped with a digital camera (DP71, Olympus) connected to a PC monitor. Individual images were of 512×512 pixels (256 gray levels), which corresponded to a tissue area of 140×140 µm (40× primary magnification). The number of AVP immunoreactive neurons in all groups were measured using an image analyzing system equipped with a computer-based CCD camera (soft ware: Optimas 6.5, CyberMetrics, Scottsdale, AZ, USA). The number of CV positive neurons of PM 8 and PM 12 were compared to those of PM 1.

The data shown represents the experimental mean±standard error (SE) for each experimental area. The difference between means were analyzed using a repeated two-way analysis of variance followed by Duncan's new multiple methods to determine differences between experimental groups. Statistical significance was considered below P<0.05.

Results

CV staining

In PM 1, PM 8 and PM 12 groups, CV positive neurons in PVN and SON appeared structurally normal (Fig. 1), and compact CV positive neurons were observed in the lateral magnocellular area of the PVN. However, small neurons were stained by CV at low density in the medial parvocellular area of the PVN. In the SON, many CV positive neurons were detectable. The distributions of CV positive neurons in the SON were similar regardless of age. However, the ventricle was morphologically different in the PM 1, PM 8, and PM 12 groups. In the PM 1 group, the 3rd ventricle was narrower than in the PM 8 and 12 groups (Fig. 1).

Blood glucose level

The blood glucose levels after fasting were 150.8±8.9 mg/dl (means±SE), 277.8±30.9 mg/dl and 189.4±11.8 mg/dl in the PM 1, PM 8, and PM 12 groups, respectively (Fig. 2). The PM 8 group had the highest blood glucose level. Significant differences were observed between blood glucose levels in the PM 1 and PM 8 groups (P<0.005) and in the PM 1 and PM 12 (P<0.01). In addition, blood glucose levels were also significant different in the PM 8 and PM 12 groups (P<0.05).

Immunohistochemistry

In the PVNs, mean numbers of AVP-positive neurons were 64.7±2.60 in the PM 1 group, 100.0±3.21 in the PM 8 group, and 105.0±1.53 in PM 12 group (Fig. 3A, C, E), and significant differences were observed between the PM 1 and PM 8 groups (P<0.01) and between the PM 1 and PM 12 groups (P<0.01) (Fig. 3G). However, no significant difference was observed between the PM 8 and PM 12 groups (Fig. 3G).

In the SONs, the mean numbers of AVP-positive neurons were 22.0±1.73 in the PM 1 group, 40.3±1.86 in the PM 8 group and 43.3±1.76 in the PM 12 group (Fig. 3B, D, F). As was observed in the PVN, significant differences for SON were found between the PM 1 and PM 8 groups (P<0.01) and between the PM 1 and PM 12 groups (P<0.01) (Fig. 3H). As well, no significant differences were observed between the PM 8 and PM 12 groups (Fig. 3H).

Changes in AVP mRNA levels

AVP mRNA expression levels in the hypothalamus of the PM 1, PM 8, and PM 12 groups are shown in Fig. 4. Changes in AVP mRNA expression values are expressed in 2^-ΔΔCT for the three groups. These were 1.02±0.088, 1.65±0.12, and 1.78±0.13, respectively. Significant differences were observed between the PM 1 and PM 8 groups (P<0.05) and between the PM 1 and PM 12 groups (P<0.01), but no significant difference was observed between the PM 8 and the PM 12 groups.

Discussion

SHRSP is a representative genetic model of cerebrovascular disease, a major cause of premature death [16], which can be classified into several types in humans. Intracerebral hemorrhage, atherothrombotic infarction, and lacunar infarction have reported that they are similar to SHRSP [17, 18]. Blood pressure in SHRSP is higher than that in SHRs [19] and these two strains differ in terms of stroke susceptibility due to an "extra" hypertensive gene and other factors that make SHRSP rats more susceptible to stroke [16]. Hyperlipidemia with hypertension is also an important risk factor for cardiovascular and cerebrovascular diseases, and is believed to cause vascular damage and progression to the hypercoagulative state [20]. In the present study, we chose PM 1, PM 8, and PM 12 SHRSP rats. The PM 1 group represented the pre-hypertensive phase, PM 8 the established hypertensive phase, and PM 12 the established hypertensive and middle aged phase [21]. Immunoreactivities and mRNA expressions of AVP as determined by immunohistochemistry and RT-qPCR gradually increased with age, although no significant differences were observed between the PM 8 and PM 12 groups. However, blood glucose levels increase to PM 8, and then reduced at PM 12. A number of studies about the relationship between diabetes mellitus and the AVP expression report that the pathological hyperglycemic conditions in animals showed a high expression of AVP compared with that of normal animals [22-25]. Accordingly, the AVP expression level might be expected to be dependent by dynamic changes of blood glucose levels, and the high AVP expression levels itself might not be necessary condition for making blood glucose level high. Küchler et al. [26] reported that AVP does not alter insulin-stimulated phosphorylation or glucose uptake in adipocytes. This study might provide clues to indicate that AVP does not influence the direct effect for regulating blood glucose by itself but cannot exclude indirect effects. Since the reason for this reduction in blood glucose levels in the middle aged group is not known so far, further studies are required to elucidate the issue.

Several studies have shown that AVP up-regulated in the diabetic brain [17, 27, 28]. Diabetes mellitus is known to be strongly associated with hypertension, which explains the up-regulation of AVP observed in the present study [11, 29]. Moreover, it has been reported that blood-brain barrier (BBB) permeability is increased by hypertension and diabetes [30-33]. Ischemia-induced edema originating from brain damage, such as, BBB disruption in stroke and hydrocephalic and vasogenic edemas in peri-infarcted hippocampal formation, is due to increased Na and Cl transport, and in addition, AVP also promotes brain edema [34, 35]. CV staining showed that the third ventricles were wider in the PM 8 and PM 12 groups than in the PM 1 group. In the PM 1 group, the third ventricles were tightly closed, whereas in the PM 8 and PM 12 groups, ependymal cells appeared to have been damaged. These morphological changes might also have been caused by an increased influx of cerebral fluid and vulnerability of BBB due to hypertension.

The results of the present study also show that AVP expression in brain is gradually elevated according to the degree of hypertension. In addition, this finding suggests that AVP up-regulation may induce blood fluid influx and edema formation.

Figures and Tables

Fig. 1

Microphotographs of cresyl violet (CV) stained neurons in the para ven tricular nucleus (PVN) and supraoptic nucleus (SON) (A-C). Neurons counts are normally dis tributed and no difference is found between neuron counts in the PVN and SON in the three study groups (D). PM, postnatal months. Scale bar=100 µm.

Fig. 2

Blood glucose levels presented as bar graphs. Glucose levels are stable between postnatal months (PM) 1 and PM 8, but are substantially lower at PM 12. Bars indicate means±SE. ^*P<0.05, ^**P<0.005.

Fig. 3

Microphotographs or arginine vasopressin (AVP) immunoreactivity in paraventricular nucleus (PVN) and supraoptic nucleus (SON) in postnatal months (PM) 1, PM 8, and PM 12 rats. Note that AVP immunoreactivities are significantly elevated in the hypothalamus in PM 8 (^*P<0.05) and PM 12 rats (^**P<0.001). (A) PM 1, (C) PM 8, and (E) PM 12 show AVP positive neurons in the PVN regions. (B) PM 1, (D) PM 8, and (F) PM 12 show AVP positive neurons in the SON regions. However, no significant difference is observed bet ween PM 8 and PM 12 rats. Scale bar=100 µm. Numbers of AVP-positive neu rons are presented as bar graphs. The bars indicate means±SE. (G) PVN, (H) SON.

Fig. 4

The relative arginine vasopressin (AVP) mRNA expressions of postnatal months (PM) 1, PM 8 and PM 12 in the hypothalamus. Figure represents 2^-ΔΔCT values. Differences between means are analyzed by repeated two-way analysis of variance followed by the Duncan's multiple-range test (n=5 per group; ^*P<0.01, ^**P<0.001). The bars indicate means±SE.

References

1. Jansen K, Van der Zee EA, Gerkema MP. Vasopressin immunoreactivity, but not vasoactive intestinal polypeptide, correlates with expression of circadian rhythmicity in the suprachiasmatic nucleus of voles. Neuropeptides. 2007. 41:207–216.

2. Keppens S, de Wulf H. The activation of liver glycogen phosphorylase by vasopressin. FEBS Lett. 1975. 51:29–32.

3. Mlynarik M, Zelena D, Bagdy G, Makara GB, Jezova D. Signs of attenuated depression-like behavior in vasopressin deficient Brattleboro rats. Horm Behav. 2007. 51:395–405.

4. Gaida W, Lang RE, Kraft K, Unger T, Ganten D. Altered neuropeptide concentrations in spontaneously hypertensive rats: cause or consequence? Clin Sci (Lond). 1985. 68:35–43.

5. Jablonskis LT, Rogers PF, Lungershausen YK, Howe PR. Chronic central administration of enalaprilat lowers blood pressure in stroke-prone spontaneously hypertensive rats. J Auton Nerv Syst. 1992. 39:119–126.

6. Jablonskis LT, Howe PR. Vasopressin compensates for acute loss of sympathetic pressor tone in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 1993. 20:380–383.

7. Rogers PF, Head GA, Lungershausen YK, Howe PR. Effects of depleting central and peripheral adrenaline stores on blood pressure in stroke-prone spontaneously hypertensive rats. J Auton Nerv Syst. 1991. 34:9–16.

8. Song J, Martin DS. Rho kinase contributes to androgen amplification of renal vasoconstrictor responses in the spon taneously hypertensive rat. J Cardiovasc Pharmacol. 2006. 48:103–109.

9. Kodama N, Komuta K, Nanba H. Can maitake MD-fraction aid cancer patients? Altern Med Rev. 2002. 7:236–239.

10. Morita M, Kita Y, Morikawa N, Iwami M, Notsu Y. Expression of arginine vasopressin and vasopressin V1a receptor mRNA in diabetic (db/db) mice. Exp Clin Endocrinol Diabetes. 2001. 109:261–266.

11. Shimamoto K, Ura N. Mechanisms of insulin resistance in hypertensive rats. Clin Exp Hypertens. 2006. 28:543–552.

12. Zelena D, Filaretova L, Mergl Z, Barna I, Tóth ZE, Makara GB. Hypothalamic paraventricular nucleus, but not vasopressin, participates in chronic hyperactivity of the HPA axis in diabetic rats. Am J Physiol Endocrinol Metab. 2006. 290:E243–E250.

13. Zelena D, Mergl Z, Makara GB. The role of vasopressin in diabetes mellitus-induced hypothalamo-pituitary-adrenal axis activation: studies in Brattleboro rats. Brain Res Bull. 2006. 69:48–56.

14. Pak TR, Chung WC, Hinds LR, Handa RJ. Arginine vasopressin regulation in pre- and postpubertal male rats by the androgen metabolite 3beta-diol. Am J Physiol Endocrinol Metab. 2009. 296:E1409–E1413.

15. Zhu H, Huang Q, Xu H, Niu L, Zhou JN. Antidepressant-like effects of sodium butyrate in combination with estrogen in rat forced swimming test: involvement of 5-HT(1A) receptors. Behav Brain Res. 2009. 196:200–206.

16. Nabika T, Cui Z, Masuda J. The stroke-prone spontaneously hypertensive rat: how good is it as a model for cerebrovascular diseases? Cell Mol Neurobiol. 2004. 24:639–646.

17. Kase CS, Mohr JP, Caplan LR. Barnett HJ, Mohr JP, Stein BM, Yatsu FM, editors. Intracerebral hemorrhage. Stroke: Pathophysiology, Diagnosis, and Management. 1998. New York: Churchill Livingstone;649–700.

18. Mohr JP, Marti-Vilalta JL. Barnett HJ, Mohr JP, Stein BM, Yatsu FM, editors. 1998. Lacunes. Stroke: Pathophysiology, Diagnosis, and Management. 1998. New York: Churchill Livingstone;599–622.

19. Fukuda S, Tsuchikura S, Iida H. Age-related changes in blood pressure, hematological values, concentrations of serum biochemical constituents and weights of organs in the SHR/Izm, SHRSP/Izm and WKY/Izm. Exp Anim. 2004. 53:67–72.

20. Gomibuchi H, Okazaki M, Iwai S, Kumai T, Kobayashi S, Oguchi K. Development of hyperfibrinogenemia in spontaneously hypertensive and hyperlipidemic rats: a potentially useful animal model as a complication of hypertension and hyperlipidemia. Exp Anim. 2007. 56:1–10.

21. Tomassoni D, Avola R, Di Tullio MA, Sabbatini M, Vitaioli L, Amenta F. Increased expression of glial fibrillary acidic protein in the brain of spontaneously hypertensive rats. Clin Exp Hypertens. 2004. 26:335–350.

22. Yibchok-anun S, Abu-Basha EA, Yao CY, Panichkriangkrai W, Hsu WH. The role of arginine vasopressin in diabetes-associated increase in glucagon secretion. Regul Pept. 2004. 122:157–162.

23. Makara GB, Mergl Z, Zelena D. The role of vasopressin in hypothalamo-pituitary-adrenal axis activation during stress: an assessment of the evidence. Ann N Y Acad Sci. 2004. 1018:151–161.

24. Yi SS, Hwang IK, Shin JH, Choi JH, Lee CH, Kim IY, Kim YN, Won MH, Park IS, Seong JK, Yoon YS. Regulatory mechanism of hypothalamo-pituitary-adrenal (HPA) axis and neuronal changes after adrenalectomy in type 2 diabetes. J Chem Neuroanat. 2010. 40:130–139.

25. Yi SS, Hwang IK, Kim YN, Kim IY, Pak SI, Lee IS, Seong JK, Yoon YS. Enhanced expressions of arginine vasopressin (Avp) in the hypothalamic paraventricular and supraoptic nuclei of type 2 diabetic rats. Neurochem Res. 2008. 33:833–841.

26. Küchler S, Perwitz N, Schick RR, Klein J, Westphal S. Arginine-vasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes. Regul Pept. 2010. 164:126–132.

27. Luo Y, Kaur C, Ling EA. Neuronal and glial response in the rat hypothalamus-neurohypophysis complex with streptozotocin-induced diabetes. Brain Res. 2002. 925:42–54.

28. Saravia FE, Gonzalez SL, Roig P, Alves V, Homo-Delarche F, De Nicola AF. Diabetes increases the expression of hypothalamic neuro peptides in a spontaneous model of type I diabetes, the nonobese diabetic (NOD) mouse. Cell Mol Neurobiol. 2001. 21:15–27.

29. Pandey NR, Benkirane K, Amiri F, Schiffrin EL. Effects of PPAR-gamma knock-down and hyperglycemia on insulin signaling in vascular smooth muscle cells from hypertensive rats. J Cardiovasc Pharmacol. 2007. 49:346–354.

30. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007. 50:202–211.

31. Ishida H, Takemori K, Dote K, Ito H. Expression of glucose transporter-1 and aquaporin-4 in the cerebral cortex of stroke-prone spontaneously hypertensive rats in relation to the blood-brain barrier function. Am J Hypertens. 2006. 19:33–39.

32. Ueno M, Sakamoto H, Liao YJ, Onodera M, Huang CL, Miyanaka H, Nakagawa T. Blood-brain barrier disruption in the hypothalamus of young adult spontaneously hypertensive rats. Histochem Cell Biol. 2004. 122:131–137.

33. Ueno M, Sakamoto H, Tomimoto H, Akiguchi I, Onodera M, Huang CL, Kanenishi K. Blood-brain barrier is impaired in the hippocampus of young adult spontaneously hypertensive rats. Acta Neuropathol. 2004. 107:532–538.

34. O'Donnell ME, Duong V, Suvatne J, Foroutan S, Johnson DM. Arginine vasopressin stimulation of cerebral microvascular endothelial cell Na-K-Cl cotransporter activity is V1 receptor and [Ca] dependent. Am J Physiol Cell Physiol. 2005. 289:C283–C292.

35. Kim J, Jung Y. Different expressions of AQP1, AQP4, eNOS, and VEGF proteins in ischemic versus non-ischemic cerebropathy in rats: potential roles of AQP1 and eNOS in hydrocephalic and vasogenic edema formation. Anat Cell Biol. 2011. 44:295–303.

TOOLS

Similar articles